The effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse/recurrence: Results of a randomised controlled trial (The PREVENT study)

Health Technology Assessment

Volumn 19, Issue 73, 2015, Pages 1-123

  Kuyken, Willem ^a   Hayes, Rachel ^b   Barrett, Barbara ^c   Byng, Richard ^d   Dalgleish, Tim ^e   Kessler, David ^f   Lewis, Glyn ^g   Watkins, Edward ^h   Morant, Nicola ⁱ   Taylor, Rod S ^b   Byford, Sarah ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^e MRC COGNITION AND BRAIN SCIENCES UNIT   (United Kingdom)

^f UNIVERSITY OF BRISTOL   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF EXETER   (United Kingdom)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ARTICLE; CHILD ABUSE; COGNITIVE THERAPY; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEPRESSION; DISEASE COURSE; DRUG USE; HEALTH CARE COST; HUMAN; INTENTION TO TREAT ANALYSIS; MAINTENANCE THERAPY; MINDFULNESS; MINDFULNESS BASED COGNITIVE THERAPY; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; PATIENT PARTICIPATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RELAPSE; STUDY DESIGN; SUICIDAL IDEATION; TREATMENT OUTCOME; ADULT; AGED; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; ECONOMICS; FEMALE; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; SINGLE BLIND PROCEDURE; TIME FACTOR; UNITED KINGDOM; YOUNG ADULT;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; COGNITIVE THERAPY; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; MINDFULNESS; PRIMARY HEALTH CARE; SECONDARY PREVENTION; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; UNITED KINGDOM; YOUNG ADULT;

EID: 84942103437     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta19730     Document Type: Article

References (124)

1. Judd LL, The clinical course of unipolar major depressive disorders. Arch Gen Psychiatry 1997;54:989–91. http://dx.doi.org/10.1001/archpsyc.1997.01830230015002
2. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007;370:851–8. http://dx.doi.org/10.1016/S0140-6736(07)61415-9
3. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: global burden of disease study. Lancet 1997;349:1498–504. http://dx.doi.org/10.1016/S0140-6736(96)07492-2
4. Layard R, Clark DM. Thrive – the Power of Evidence-Based Psychological Therapies. London: Penguin Group; 2014.
5. Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett DB, Mallinger AG, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47:1093–9. http://dx.doi.org/10.1001/archpsyc.1990.01810240013002
6. Kupfer DJ, Frank E, Perel JM, Cornes C, Mallinger AG, Thase ME, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49:769–73. http://dx.doi.org/10.1001/archpsyc.1992.01820100013002
7. Vos T, Haby MM, Barendregt JJ, Kruijshaar M, Corry J. Andrews G The burden of major depression avoidable by longer-term treatment strategies. Arch Gen Psychiatry 2004;61:1097–103. http://dx.doi.org/10.1001/archpsyc.61.11.1097
8. National Institute for Health and Care Excellence. Depression: the Treatment and Management of Depression in Adults (Update). Clinical guideline London: NICE; 2009.
9. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361:653–61. http://dx.doi.org/10.1016/S0140-6736(03)12599-8
10. Dawe HA. Teaching – social science or performing art. Harvard Educ Rev 1984;54:111–14.
11. Katon W, Rutter C, Ludman EJ, Von Korff M, Lin E, Simon G, et al. A randomized trial of relapse prevention of depression in primary care. Arch Gen Psychiatry 2001;58:241–7. http://dx.doi.org/10.1001/archpsyc.58.3.241
12. van Schaik DJF, Klijn AF, van Hout HPJ, van Marwijk HW, Beekman AT, de Haan M, et al. Patients’ preferences in the treatment of depressive disorder in primary care. Gen Hosp Psychiatry 2004;26:184–9. http://dx.doi.org/10.1016/j.genhosppsych.2003.12.001
13. Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry 2006;163:101–8. http://dx.doi.org/10.1176/appi.ajp.163.1.101
14. Cooper C, Bebbington P, King M, Brugha T, Meltzer H, Bhugra D, et al. Why people do not take their psychotropic drugs as prescribed: results of the 2000 National Psychiatric Morbidity Survey. Acta Psychiatr Scand 2007;116:47–53. http://dx.doi.org/10.1111/j.1600-0447.2006.00974.x
15. Clark DM, Layard R, Smithies R, Richards DA, Suckling R, Wright B. Improving access to psychological therapy: initial evaluation of two UK demonstration sites. Behav Res Ther 2009;47:910–20. http://dx.doi.org/10.1016/j.brat.2009.07.010
16. Layard R. The case for psychological treatment centres. BMJ 2006;332:1030–2. http://dx.doi.org/10.1136/bmj.332.7548.1030
17. Cuijpers P, van Straten A, van Schaik A, Andersson G. Psychological treatment of depression in primary care: a meta-analysis. Br J Gen Pract 2009;59:120–7. http://dx.doi.org/10.3399/bjgp09X395139
18. Hollon SD, Muñoz RF, Barlow DH, Beardslee WR, Bell CC, Bernal G, et al. Psychosocial intervention development for the prevention and treatment of depression: promoting innovation and increasing access. Biol Psychiatry 2002;52:610–30. http://dx.doi.org/10.1016/S0006-3223(02)01384-7
19. Hirschfeld RMA, Keller MB, Panico S, Arons BS, Barlow D, Davidoff F, et al. The National Depressive and Manic–Depressive Association consensus statement on the undertreatment of depression. JAMA 1997;277:333–40. http://dx.doi.org/10.1001/jama.1997.03540280071036
20. Segal ZV, Williams JMG, Teasdale JD. Mindfulness-Based Cognitive Therapy for Depression, 2nd edn. New York, NY: Guilford Press; 2013.
21. The Mindfulness Initiative. URL: www.themindfulnessinitiative.org.uk/ (accessed 8 October 2014).
22. Rycroft-Malone J, Anderson R, Crane R, Gibson A, Gradinger F, Griffiths HO, et al. Accessibility and implementation in UK services of an effective depression relapse prevention programme – mindfulness-based cognitive therapy (MBCT): ASPIRE study protocol. Implement Sci 2014;9:62. http://dx.doi.org/10.1186/1748-5908-9-62
23. Crane RS, Kuyken W. The implementation of mindfulness-based cognitive therapy: learning from the UK health service experience. Mindfulness 2013;4:246–54. http://dx.doi.org/10.1007/s12671-012-0121-6
24. Teasdale J, Segal Z, Williams J, Ridgeway V, Soulsby J, Lau M. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol 2000;68:615–23. http://dx.doi.org/10.1037/0022-006X.68.4.615
25. Ma SH, Teasdale JD. Mindfulness-based cognitive therapy for depression: replication and exploration of differential relapse prevention effects. J Consult Clin Psychol 2004;72:31–40. http://dx.doi.org/10.1037/0022-006X.72.1.31
26. Coelho HF, Canter PH, Ernst E. Mindfulness-based cognitive therapy: evaluating current evidence and informing future research. J Consult Clin Psychol 2007;75:1000–5. http://dx.doi.org/10.1037/0022-006X.75.6.1000
27. Kuyken W. MRC Final Report: Brain Sciences II Trial Platform ‘Preventing Depression Relapse in NHS Practice Using Mindfulness-Based Cognitive Therapy’. London: Medical Research Council; 2007.
28. Kuyken W, Byford S, Taylor RS, Watkins E, Holden E, White K, et al. Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. J Consult Clin Psychol 2008;76:966–78. http://dx.doi.org/10.1037/a0013786
29. White K, Holden ER, Byng R, Mullan E, Kuyken W. Under/over-recruitment to mental health trials. Acta Psychiatr Scand 2007;116:158. http://dx.doi.org/10.1111/j.1600-0447.2007.01061.x
30. Allen M, Bromley A, Kuyken W, Sonnenberg SJ. Participants’ experiences of mindfulness-based cognitive therapy: ‘It changed me in just about every way possible’. Behav Cogn Psychother 2009;37:413–30. http://dx.doi.org/10.1017/S135246580999004X
31. Liu CF, Hedrick SC, Caheny EF, Heagerty P, Felker B, Hasenberg N, et al. Cost-effectiveness of collaborative care for depression in a primary care veteran population. Psychiatr Serv 2003;54:698–704. http://dx.doi.org/10.1176/appi.ps.54.5.698
32. Simon GE, Katon WJ, VonKorff M, Unützer J, Lin EH, Walker EA, et al. Cost-effectiveness of a collaborative care program for primary care patients with persistent depression. Am J Psychiatry 2001;158:1638–44. http://dx.doi.org/10.1176/appi.ajp.158.10.1638
33. Simon GE, Von Korff M, Ludman EJ, Katon WJ, Rutter C, Unützer J, et al. Cost-effectiveness of a program to prevent depression relapse in primary care. Med Care 2002;40:941–50. http://dx.doi.org/10.1097/00005650-200210000-00011
34. Segal Z, Williams J, Teasdale J. Mindfulness-Based Cognitive Therapy for Depression: A New Approach to Preventing Relapse. New York, NY: Guilford Press; 2002.
35. Segal ZV, Kennedy S, Gemar M, Hood K, Pedersen R, Buis T. Cognitive reactivity to sad mood provocation and the prediction of depressive relapse. Arch Gen Psychiatry 2006;63:749–55. http://dx.doi.org/10.1001/archpsyc.63.7.749
36. Feldman C, Kuyken W. Compassion in the landscape of suffering. Contemp Buddhism 2011;12:143–55. http://dx.doi.org/10.1080/14639947.2011.564831
37. Kuyken W, Watkins E, Holden E, White K, Taylor RS, Byford S, et al. How does mindfulness-based cognitive therapy work? Behav Res Ther 2010;48:1105–12. http://dx.doi.org/10.1016/j.brat.2010.08.003
38. Chambers R, Gullone E, Allen NB. Mindful emotion regulation: an integrative review. Clin Psychol Rev 2009;29:560–72. http://dx.doi.org/10.1016/j.cpr.2009.06.005
39. Raes F, Dewulf D, Van Heeringen C, Williams JM. Mindfulness and reduced cognitive reactivity to sad mood: evidence from a correlational study and a non-randomized waiting list controlled study. Behav Res Ther 2009;47:623–7. http://dx.doi.org/10.1016/j.brat.2009.03.007
40. Farb NAS, Anderson AK, Mayberg H, Bean J, McKeon D, Segal ZV. Minding one’s emotions: mindfulness training alters the neural expression of sadness. Emotion 2010;10:25–33. http://dx.doi.org/10.1037/a0017151
41. Kuyken W, Crane R, Dalgleish T. Does mindfulness based cognitive therapy prevent relapse of depression? BMJ 2012;345:e7194. http://dx.doi.org/10.1136/bmj.e7194
42. Kabat-Zinn J. Full Catastrophe Living: How to Cope with Stress, Pain and Illness using Mindfulness Meditation. New York, NY: Delacorte; 1990.
43. Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive Therapy of Depression. New York, NY: Guilford Press; 1979.
44. Hollon SD, DeRubeis RJ, Shelton RC, Amsterdam JD, Salomon RM, O’Reardon JP, et al. Prevention of relapse following cognitive therapy vs. medications in moderate to severe depression. Arch Gen Psychiatry 2005;62:417–22. http://dx.doi.org/10.1001/archpsyc.62.4.417
45. Lau MA, Segal ZV, Williams JM. Teasdale’s differential activation hypothesis: implications for mechanisms of depressive relapse and suicidal behaviour. Behav Res Ther 2004;42:1001–17. http://dx.doi.org/10.1016/j.brat.2004.03.003
46. Jarrett RB, Kraft D, Doyle J, Foster BM, Eaves GG, Silver PC. Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial. Arch Gen Psychiatry 2001;58:381–8. http://dx.doi.org/10.1001/archpsyc.58.4.381
47. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-Patient Edition (SCID-I/NP). New York, NY: Biometrics Research, New York State Psychiatric Institute; November 2002.
48. Joint Formulary Committee. British National Formulary, 63rd edn. London: BMJ Group and Pharmaceutical Press; 2012.
49. Williams JBW, Kobak KA, Bech P, Engelhardt N, Evans K, Lipsitz J, et al. The GRID-HAMD: standardization of the Hamilton Depression Rating Scale. Int Clin Psychopharmacol 2008;23:120–9. http://dx.doi.org/10.1097/YIC.0b013e3282f948f5
50. Judd LL, Paulus MP, Zeller P. The role of residual subthreshold depressive symptoms in early episode relapse in unipolar major depressive disorder. Arch Gen Psychiatry 1999;56:764–5. http://dx.doi.org/10.1001/archpsyc.56.8.763
51. Segal ZV, Bieling P, Young T, MacQueen G, Cooke R, Martin L, et al. Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Arch Gen Psychiatry 2010;67:1256–64. http://dx.doi.org/10.1001/archgenpsychiatry.2010.168
52. Crane RS, Eames C, Kuyken W, Hastings RP, Williams JM, Bartley T, et al. Development and validation of the mindfulness-based interventions – teaching assessment criteria (MBI:TAC). Assessment 2013;20:681–8. http://dx.doi.org/10.1177/1073191113490790
53. Segal ZV, Teasdale JD, Williams JM, Gemar MC. The mindfulness-based cognitive therapy adherence scale: inter-rater reliability, adherence to protocol and treatment distinctiveness. Clin Psychol Psychother 2002;9:131–8. http://dx.doi.org/10.1002/cpp.320
54. Keller MB, Lavori PW, Friedman B, Nielsen E, Endicott J, McDonald-Scott P, et al. The longitudinal interval follow-up evaluation – a comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry 1987;44:540–8. http://dx.doi.org/10.1001/archpsyc.1987.01800180050009
55. Beck AT, Steer RA, Brown GK. The Beck Depression Inventory – Second Edition. San Antonio, TX: Psychological Corporation; 1996.
56. Kabat-Zinn J. An outpatient program in behavioral medicine for chronic pain patients based on the practice of mindfulness meditation – theoretical considerations and preliminary results. Gen Hosp Psychiatry 1982;4:33–47. http://dx.doi.org/10.1016/0163-8343(82)90026-3
57. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53–72. http://dx.doi.org/10.1016/0168-8510(96)00822-6
58. EuroQol Group. A new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208. http://dx.doi.org/10.1016/0168-8510(90)90421-9
59. Harper A, Power M. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med 1998;28:551–8. http://dx.doi.org/10.1017/S0033291798006667
60. Orley J, Harper A, Power M, Billington R. Development of the WHOQOL-BREF quality of life assessment. Qual Life Res 1997;6:273.
61. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62. http://dx.doi.org/10.1136/jnnp.23.1.56
62. Walter SD, Eliasziw M, Donner A. Sample size and optimal designs for reliability studies. Stat Med 1998;7:101–10. http://dx.doi.org/10.1002/(SICI)1097-0258(19980115)17:1<101::AID-SIM727>3.0.CO;2-E
63. O’Hara MW, Rehm LP. Hamilton Rating Scale for Depression: reliability and validity of judgements of novice raters. J Consult Clin Psychol 1983;51:318–19. http://dx.doi.org/10.1037/0022-006X.51.2.318
64. Kabat-Zinn J. Chapman-Waldrop A. Compliance with an outpatient stress reduction program: rates and predictors of program completion. J Behav Med 1988;11:333–52. http://dx.doi.org/10.1007/BF00844934
65. Kabat-Zinn J, Lipworth L, Burney R. The clinical use of mindfulness meditation for the selfregulation of chronic pain. J Behav Med 1985;8:163–90. http://dx.doi.org/10.1007/BF00845519
66. Kabat-Zinn J, Massion AO, Kristeller J, Peterson LG, Fletcher KE, Pbert L, et al. Effectiveness of a meditation-based stress reduction program in the treatment of anxiety disorders. Am J Psychiatry 1992;149:936–43. http://dx.doi.org/10.1176/ajp.149.7.936
67. Williams KA, Kolar MM, Reger BE, Pearson JC. Evaluation of a wellness-based mindfulness stress reduction intervention: a controlled trial. Am J Health Promot 2001;15:422–32. http://dx.doi.org/10.4278/0890-1171-15.6.422
68. Bower P, Byford S, Sibbald B, Ward E, King M, Lloyd M, et al. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. II: cost-effectiveness. BMJ 2000;321:1389–92. http://dx.doi.org/10.1136/bmj.321.7273.1389
69. Konig HH, Bernert S, Angermeyer MC. Measuring preferences for depressive health states: a comparison of the EuroQol instrument, time-trade-off and contingent valuation. Psychiatr Prax 2005;32:122–31.
70. Kuyken W, Orley J. Development of the WHOQOL – rationale and current status. Int J Ment Health 1994;23:24–56.
71. Kuyken W, Orley J, Power M, Herman H, Schofield H, Murphy B, et al. The World Health Organization Quality of Life Assessment (WHOQOL) – position paper from the World Health Organization. Soc Sci Med 1995;41:1403–9. http://dx.doi.org/10.1016/0277-9536(95)00112-K
72. Baer RA. Mindfulness training as a clinical intervention: a conceptual and empirical review. Clin Psychol Sci Pract 2003;10:125–43. http://dx.doi.org/10.1093/clipsy.bpg015
73. Grossman P, Niemann L, Schmidt S, Walach H. Mindfulness-based stress reduction and health benefits. J Psychosom Res 2004;57:35–43. http://dx.doi.org/10.1016/S0022-3999(03)00573-7
74. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Statistical Principles for Clinical Trials. Guideline E9; 1998. URL: www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf (accessed 20 July 2015).
75. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P, CONSORT group. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med 2008;148:295–309. http://dx.doi.org/10.7326/0003-4819-148-4-200802190-00008
76. Schulz KF, Altman DG, Moher D, CONSORT group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010;152:1–15. http://dx.doi.org/10.7326/0003-4819-152-11-201006010-00232
77. Parker G, Roussos J, HadziPavlovic D, Mitchell P, Wilhelm K, Austin MP. The development of a refined measure of dysfunctional parenting and assessment of its relevance in patients with affective disorders. Psychol Med 1997;27:1193–1203. http://dx.doi.org/10.1017/S003329179700545X
78. Kuyken W, Byford S, Byng R, Dalgleish T, Lewis G, Taylor R, et al. Study protocol for a randomized controlled trial comparing mindfulness-based cognitive therapy with maintenance anti-depressant treatment in the prevention of depressive relapse/recurrence: the PREVENT trial. Trials 2010;11:99. http://dx.doi.org/10.1186/1745-6215-11-99
79. Dodd S, White I, Williamson P. Nonadherence to treatment protocol in published randomised controlled trials: a review. Trials 2012;13:84. http://dx.doi.org/10.1186/1745-6215-13-84
80. Choi SC, Lu IL. Effect of non-random missing data mechanisms in clinical trials. Stat Med 1995;14:2675–84. http://dx.doi.org/10.1002/sim.4780142407
81. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999;8:3–15. http://dx.doi.org/10.1191/096228099671525676
82. Great Britain. Data Protection Act. London: The Stationery Office; 1998.
83. Kuyken W, Byford S, Byng R, Dalgleish T, Lewis G, Taylor R, et al. Update to the study protocol for a randomized controlled trial comparing mindfulness-based cognitive therapy with maintenance anti-depressant treatment in the prevention of depressive relapse/recurrence: the PREVENT trial. Trials 2014;15:217. http://dx.doi.org/10.1186/1745-6215-15-217
84. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal. London: NICE; 2013.
85. Kessler D, Barber C, Birnbaum HG, Frank RG, Greenberg PE, Rose RM, et al. Depression in the workplace: effects on short-term disability. Health Aff (Millwood) 1999;18:163–71. http://dx.doi.org/10.1377/hlthaff.18.5.163
86. Kind P. The EuroQol Instrument: An Index of Health Related Quality of Life. In Spilker B, editor. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn. Philadelphia, PA: Lippincott-Raven; 1996.
87. Mulhern B, Mukuria C, Barkham M, Knapp M, Byford S, Soeteman D, et al. Using generic preference-based measures in mental health: psychometric validity of the EQ-5D and SF-6D. Br J Psychiatry 2014;205:236–43. http://dx.doi.org/10.1192/bjp.bp.112.122283
88. Dolan P, Gudex C, Kind P, Williams A. A Social Tariff for EuroQoL: Results from a UK General Population Survey. York: Centre for Health Economics, University of York; 1995.
89. Richardson G, Manca A. Calculation of quality-adjusted life-years in the published literature: a review of methodology and transparency. Health Econ 2004;13:1203–10. http://dx.doi.org/10.1002/hec.901
90. Curtis L. Unit Costs of Health and Social Care 2013. Canterbury: PSSRU, University of Kent; 2013.
91. Kessler RC, Barber C, Beck A, Berglund P, Cleary PD, McKenas D, et al. The World Health Organization Health and Work Performance Questionnaire (HPQ). J Occupat Environ Med 2003;45:156–74. http://dx.doi.org/10.1097/01.jom.0000052967.43131.51
92. Netten A, Knight J, Dennett J, Cooley R, Slight A. A Ready Reckoner for Staff Costs in the NHS. Canterbury: University of Kent; 1998.
93. Barrett B, Byford S. The challenges of estimating the unit cost of group based therapies. In Curtis L, editor. Unit Costs of Health and Social Care 2008. Canterbury: PSSRU, University of Kent; 2008.
94. Joint Formulary Committee. British National Formulary, 60th edn. London: BMJ Group and Pharmaceutical Press; 2010.
95. Department of Health. NHS Reference Costs 2012–2013. London: Department of Health; 2013.
96. Koopmanschap MA, Rutten FFH. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996;10:460–6. http://dx.doi.org/10.2165/00019053-199610050-00003
97. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York, NY: Chapman & Hall; 1993. http://dx.doi.org/10.1007/978-1-4899-4541-9
98. Thompson SG, Barber JA How should cost data in pragmatic randomised trials be analysed? BMJ 2000;320:1197–200. http://dx.doi.org/10.1136/bmj.320.7243.1197
99. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 2005.
100. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000;19:3219–36. http://dx.doi.org/10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P
101. Fenwick E, Byford S A guide to cost-effectiveness acceptability curves. Br J Psychiatry 2005;187:106–108. http://dx.doi.org/10.1192/bjp.187.2.106
102. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779–87. http://dx.doi.org/10.1002/hec.635
103. Kazdin AE. Mediators and mechanisms of change in psychotherapy research. Ann Rev Clin Psychol 2007;3:1–27. http://dx.doi.org/10.1146/annurev.clinpsy.3.022806.091432
104. Baer RA, Smith GT, Hopkins J, Krietemeyer J, Toney L. Using self-report assessment methods to explore facets of mindfulness. Assessment 2006;13:27–45. http://dx.doi.org/10.1177/1073191105283504
105. Kraemer HC, Wilson GT, Fairburn CG, Agras WS. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry 2002;59:877–83. http://dx.doi.org/10.1001/archpsyc.59.10.877
106. Murphy R, Cooper Z, Hollon SD, Fairburn CG. How do psychological treatments work? Investigating mediators of change. Behav Res Ther 2009;47:1–5. http://dx.doi.org/10.1016/j.brat.2008.10.001
107. Garratt G, Ingram RE, Rand KL, Sawalani G. Cognitive processes in cognitive therapy: evaluation of the mechanisms of change in the treatment of depression. Clin Psychol Sci Pract 2007;14:224–39. http://dx.doi.org/10.1111/j.1468-2850.2007.00081.x
108. Cox DR. Regression models and life tables. J R Stat Soc Ser B Stat Methodol 1972;34:187–220.
109. Mackinnon DP. Introduction to Statistical Mediation Analysis. New York, NY: Lawrence Erlbaum Associates; 2008.
110. O’Cathain A, Thomas KJ, Drabble SJ, Rudolph A, Hewison J. What can qualitative research do for randomised controlled trials? A systematic mapping review. BMJ Open 2013;3:e002889. http://dx.doi.org/10.1136/bmjopen-2013-002889
111. Finucane A, Mercer S. An exploratory mixed methods study of the acceptability and effectiveness of mindfulness-based cognitive therapy for patients with active depression and anxiety in primary care. BMC Psychiatry 2006;6:14. http://dx.doi.org/10.1186/1471-244X-6-14
112. Mason O, Hargreaves I. A qualitative study of mindfulness-based cognitive therapy for depression. Br J Med Psychol 2001;74:197–212. http://dx.doi.org/10.1348/000711201160911
113. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77–101. http://dx.doi.org/10.1191/1478088706qp063oa
114. Hertenstein E, Rose N, Voderholzer U, Heidenreich T, Nissen C, Thiel N, et al. Mindfulness-based cognitive therapy in obsessive–compulsive disorder – a qualitative study on patients’ experiences. BMC Psychiatry 2012;12:185. http://dx.doi.org/10.1186/1471-244X-12-185
115. Flick U. An Introduction to Qualitative Research. 3rd edn. London: Pine Forge Press; 2006.
116. Piet J, Hougaard E. The effect of mindfulness-based cognitive therapy for prevention of relapse in recurrent major depressive disorder: a systematic review and meta-analysis. Clin Psychol Rev 2011;31:1032–40. http://dx.doi.org/10.1016/j.cpr.2011.05.002
117. Williams JMG, Crane C, Barnhofer T, Brennan K, Duggan DS, Fennell MJ, et al. Mindfulness-based cognitive therapy for preventing relapse in recurrent depression: a randomized dismantling trial. J Consult Clin Psychol 2014;82:275–86. http://dx.doi.org/10.1037/a0035036
118. Shawyer F, Meadows GN, Judd F, Martin PR, Segal Z, Piterman L. The DARE study of relapse prevention in depression: design for a phase 1/2 translational randomised controlled trial involving mindfulness-based cognitive therapy and supported self monitoring. BMC Psychiatry 2012;12:3. http://dx.doi.org/10.1186/1471-244X-12-3
119. Meadows GN, Shawyer F, Enticott JC, Graham AL, Judd F, Martin PR, et al. Mindfulness-based cognitive therapy for recurrent depression: a translational research study with 2-year follow-up. Aust N Z J Psychiatry 2014;48:743–55. http://dx.doi.org/10.1177/0004867414525841
120. Huijbers MJ, Spijker J, Donders AR, van Schaik DJ, van Oppen P, Ruhé HG, et al. Preventing relapse in recurrent depression using mindfulness-based cognitive therapy, antidepressant medication or the combination: trial design and protocol of the MOMENT study. BMC Psychiatry 2012;12:125. http://dx.doi.org/10.1186/1471-244X-12-125
121. Stangier U, Hilling C, Heidenreich T, Risch AK, Barocka A, Schlösser R, et al. Maintenance cognitive-behavioral therapy and manualized psychoeducation in the treatment of recurrent depression: a multicenter prospective randomized controlled trial. Am J Psychiatry 2013;170:624–32. http://dx.doi.org/10.1176/appi.ajp.2013.12060734
122. Miniati M, Rucci P, Benvenuti A, Frank E, Buttenfield J, Giorgi G, et al. Clinical characteristics and treatment outcome of depression in patients with and without a history of emotional and physical abuse. J Psychiatr Res 2010;44:302–9. http://dx.doi.org/10.1016/j.jpsychires.2009.09.008
123. Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry 2000;157:229–33. http://dx.doi.org/10.1176/appi.ajp.157.2.229
124. Bockting CL, Schene AH, Spinhoven P, Koeter MW, Wouters LF, Huyser J, et al. Preventing relapse/recurrence in recurrent depression with cognitive therapy: a randomized controlled trial. J Consult Clin Psychol 2005;73:647–57. http://dx.doi.org/10.1037/0022-006X.73.4.647